Infliximab

BNF:
10.1.3
Status:
Red
Decision Date:
None
 

Comments

RED: hospital use only.

(Remicade (reference infliximab product), Remsima and Inflectra (biosimilars) are available for use as per NICE TA329 - Ulcerative Colitis and NICE TA373 - RA) (Decision date - March 2015)

RED:1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)

RED1,2,3: NICE TA383 for ankylosing spondylitis and non-radiographic axial spondyloarthritis.  (Decision date - March 2016)

RED1,2,3: NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app